A
Alzheon
United States · Biotech
Alzheon develops oral medicines for Alzheimer’s disease and other neurodegenerative disorders.
Product
Alzheon is a clinical-stage biopharmaceutical company pursuing small-molecule treatments for neurodegenerative diseases. Its research focuses on preventing the formation of toxic protein aggregates.
Its development pipeline includes valiltramiprosate, also called ALZ-801, and the earlier-stage ALZ-507 program. The company is based in Framingham, Massachusetts.
Funding history
1 round · 1 with disclosed amounts| Announced | Round | Amount | Investors |
|---|---|---|---|
| Equity offering disclosure | $78.8M | Participants not disclosed |